Adiso Therapeutics Announces Data Publication of Two Phase 1 Studies of First-in-Class Neutrophil Modulator ADS051 in the American Journal of Gastroenterology
ADS051 was demonstrated to be safe in a single ascending dose (SAD) study in healthy volunteers across five dosing cohorts
CONCORD, Mass., March 6, 2025 /PRNewswire/ -- Adiso Therapeutics, Inc. announced the publication of the results of two Phase 1 studies, which showed that healthy subjects and ulcerative colitis (UC) patients given oral doses of ADS051, a novel modulator of neutrophils being developed for Inflammatory Bowel Disease (IBD), could be safely administered and well-tolerated in IBD patients. These studies showed consistent safety and tolerability of ADS051 with highly encouraging signals of clinical response as determined by Mayo Endoscopic Scoring blinded to the investigator. Data from the two trials has been published in the American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG).
The first of the two publications presents the results from the single ascending dose (SAD) trial of ADS051. This trial was the intensive first in human study of ADS051 across five (5) dosing cohorts of healthy subjects and included a deep-reaching pharmacokinetic analysis of this first and only modulator of neutrophils. There were no dose-limiting toxicities, serious adverse events (AEs), or trial discontinuation due to AEs. Pharmacokinetic data demonstrated minimal systemic absorption of ADS051, with the majority of drug excreted in the stool as expected. There was no clinical evidence of adverse immunosuppressive activity.
The second publication presents the results of a multiple ascending dose (MAD) study of ADS051 in patients with moderately to severely active UC. The MAD study included three (3) placebo controlled dosing cohorts, measuring signals of clinical response using assessments typical for later stage studies, such as Mayo Endoscopic Scoring which included Clinical Remission (CR), Endoscopic Improvement (EI), and Endoscopic Response (ER). The study also looked at neutrophil-related markers of inflammation and histologic assessment. As detailed in the publication, this study achieved its primary endpoint of safety and tolerability with encouraging signs of efficacy across multiple outcome measures.
"The SAD publication documents the successful completion of a very important first step in establishing patient safety. The completion of the study provided an understanding and foundation for safe dosing of ADS051 prior to exposure in patients with IBD," said Adam Cheifetz, M.D., Director, Center for Inflammatory Bowel Disease, Beth Israel Lahey Health, Beth Israel Deaconess Medical Center, Harvard Medical School Teaching Hospital.
"UC is an inflammatory disease with complex underlying biology. We are now amid a rapidly expanding therapeutic landscape of treatment options for individuals with IBD, yet ADS051 is different and represents a unique therapeutic approach of neutrophil modulation," said Jessica Allegretti, MD, MPH., Crohn's and Colitis Center, Associate Professor of Medicine, Harvard Medical School, Gastroenterology, Hepatology and Endoscopy, Internal Medicine, Brigham and Women's Hospital. "Participants in the multiple ascending dose (MAD) trial with moderately to severely active UC were repeatedly dosed with ADS051. Highly favorable signals of pharmacologic activity and clinical benefit were seen over a relatively short 28-day period. These Phase 1b MAD data indicate that ADS051 may represent an important therapeutic advancement as a safe and effective, once-daily oral therapy for patients with UC." ADS051 is a novel, oral, gut-restricted, small molecule consisting of an active moiety or warhead, covalently linked to a 2,000 molecular weight polyethylene glycol (PEG). ADS051 inhibits two neutrophil-related receptors, multidrug resistant protein 2 (MRP2) which activates hepoxilin A3 (HXA3) neutrophil recruitment or transmigration and formyl peptide receptor 1 (FPR1), a known GPCR found on the surface of neutrophils, important for activation and signaling recruitment. Due to the design of ADS051, it largely remains in the colonic lumen, avoiding wide-spread systemic exposure and subsequent T-cell activation or general immunosuppression. Unlike currently available therapies, ADS051 is intended to positively affect neutrophil-mediated tissue damage, a hallmark of IBD pathology.
The ADS051 data generated from these two studies has been submitted to the United States (U.S.) Food and Drug Administration (FDA) within an end-of-Phase 1 meeting. Adiso is currently planning a Phase 2 trial for the treatment of moderately to severely active UC in adults.
Publication Links: Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study (Open Press), Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial (Open Press)
About ADS051
ADS051 is a novel, oral, gut-restricted, small molecule that blocks multidrug resistant protein 2 (MRP2)/hepoxilin A3 (HXA3) and formyl peptide receptor 1 (FPR1) mediated neutrophil epithelial transmigration and activation in human cell-based systems. Its lack of both systemic exposure and blockage of T cell activation is intended to limit general immunosuppression. Unlike currently available therapies, it addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a Phase 1b MAD study in patients with moderate to severe ulcerative colitis, ADS051 demonstrated favorable safety and tolerability administered orally, once daily, in patients with moderate-to-severe UC. PK data demonstrated that ADS051 is gut-restricted, as designed, with minimal systemic drug exposure. ADS051 efficacy measures indicate encouraging signals of pharmacologic activity and clinical benefit versus placebo after 28 days of treatment. The Phase 1b MAD data indicate that ADS051 may be an important therapeutic advancement as a safe and effective, once-daily oral therapy for patients with UC. Adiso is currently pursuing additional investigation of ADS051 in a larger Phase 2 clinical study.
About Adiso
Adiso is a clinical-stage biopharmaceutical company dedicated to improving the health of patients suffering from debilitating inflammatory diseases. This dedication is epitomized by our lead clinical candidates, ADS051, an oral gut-restricted modulator of neutrophil trafficking and activation via inhibition of MRP2 and FPR1 for the treatment of inflammatory bowel disease; and ADS032, a dual NLRP1/NLRP3 inflammasome inhibitor initially being developed for inflammatory diseases of the lung. Adiso has built these development programs upon a rich history of institutional and academic collaboration, including the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia, the University of Edinburgh Centre for Inflammation Research and the University College Cork, Ireland, the APC Microbiome Institute. For more information, please visit www.adisotx.com or our LinkedIn page www.linkedin.com/company/adisotx/
Refer to: Scott Megaffin; pr@adisotx.com (media)
View original content to download multimedia:https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-data-publication-of-two-phase-1-studies-of-first-in-class-neutrophil-modulator-ads051-in-the-american-journal-of-gastroenterology-302393958.html
SOURCE Adiso Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Simple Recipe Swaps for a Healthier You
MISSION, Kan., Aug. 4, 2025 /PRNewswire/ -- (Family Features) If the idea of overhauling your family's menu is stopping you from making healthier choices in the kitchen, you might find relief in knowing simple swaps are all it takes. Instead of sweeping changes that require all new recipes, just changing an ingredient or two in your favorite dishes can put you on a path toward better nutrition. You can boost the nutritional value of meals and support your heart health by making smart substitutions – like using whole grains, healthy oils and lower-sodium options – to reduce saturated fat, added sugars and sodium while adding beneficial nutrients like fiber, protein and healthy fats. Another nutrition-conscious swap you can make easily is opting for fat-free or low-fat plain Greek yogurt in place of full-fat sour cream and other dairy products. A single serving typically provides 10 or more grams of protein and roughly 13% of the daily recommended value of calcium. In fact, according to the American Heart Association, a balanced diet that includes regular consumption of unsweetened, nonfat, plain yogurt for individuals with hypertension may help improve blood pressure outcomes. Start doing your heart a favor with these favorites that replace full-fat ingredients with low-fat or nonfat Greek yogurt, helping you reduce calorie intake and fat content without compromising flavor. Mango and Pineapple Tropical Parfaits capture the flavors of ripe fruit, silky yogurt and crunchy granola in every spoonful of paradise while ruby-red pomegranate and coconut top off this island treasure. Fruity Oatmeal Yogurt Parfaits provide a protein-packed breakfast to start busy days while Frozen Yogurt Bark – a chilled delight with less than 100 calories per serving – helps you indulge without overdoing it. A diet that involves smart swaps like these may contribute to heart health, per the American Heart Association, by providing essential nutrients and supporting healthy blood pressure levels – meaning you're just a few ingredient substitutions away from enjoying a more nutritious, yet still delicious menu. These yogurt-inspired recipes were developed as part of the American Heart Association's Healthy for Good Eat Smart initiative, which is nationally supported by Danone. Discover more easy, flavor-packed ways to make your favorite recipes healthier for your heart at Mango and Pineapple Tropical ParfaitsRecipe courtesy of the American Heart AssociationServings: 4 (1 parfait per serving) 1 medium mango, peeled and chopped2 cups nonfat plain Greek yogurt1/2 cup low-fat, no-added-sugar granola1/2 cup diced pineapple1 medium banana, sliced1/4 cup pomegranate seeds or arils2 tablespoons unsweetened flaked coconut In each parfait glass, layer 1/4 mango, 1/4 cup yogurt, 1 tablespoon granola, 2 tablespoons pineapple, 1/4 banana slices and 1/4 cup yogurt. Top with remaining granola. Sprinkle with pomegranate seeds and coconut. Serve immediately for peak flavor and texture. Nutritional information per serving: 230 calories: 6 g total fat; 82 mg sodium; 33 g carbohydrates; 5 g fiber; 24 g total sugars; 13 g protein. Fruity Oatmeal Yogurt ParfaitsRecipe courtesy of the American Heart AssociationServings: 4 (1 parfait per serving) 2 cups fresh or frozen sliced, hulled strawberries, thawed and patted dry if frozen2 cups fresh or frozen blueberries, halved blackberries or both, thawed and patted dry if frozen1 tablespoon, plus 1 teaspoon, honey2 teaspoons ground cinnamon2 cups water1 cup uncooked rolled oats2 cups nonfat plain Greek yogurt In medium bowl, gently stir strawberries, blueberries, honey and cinnamon. In medium saucepan over medium-high heat, bring water and oats to boil. Boil 5 minutes, stirring occasionally. In each parfait glass, layer 1/4 cup oatmeal, 1/4 cup fruit mixture, 1/4 cup yogurt and 1/4 cup fruit mixture. Repeat layers. Nutritional information per serving: 238 calories; 2 g total fat; 6 mg cholesterol; 47 mg sodium; 42 mg carbohydrates; 6 g fiber; 21 g total sugars; 16 g protein. Frozen Yogurt BarkRecipe courtesy of the American Heart AssociationServings: 8 1 1/2 cups low-fat, no-sugar-added vanilla Greek yogurt2 tablespoons honey or pure maple syrup2 tablespoons chopped unsalted almonds1/2 cup finely chopped mango1/2 cup blueberries1/4 cup blackberries or raspberries, chopped if large In medium bowl, whisk yogurt and honey until combined. Line 13-by-9-by-2-inch baking dish with parchment paper. Using spatula or knife, spread yogurt mixture over paper as thinly as possible. Sprinkle almonds over yogurt mixture. Using fingertips, gently press almonds into yogurt mixture. Sprinkle with mango, blueberries and raspberries. Using fingertips, gently press fruit into yogurt mixture. Cover dish with plastic wrap or aluminum foil. Freeze overnight. For serving, remove baking dish from freezer. Gently lift parchment paper from dish and transfer to cutting board. Using hands, break bark into pieces or hit lightly on surface of cutting board. Serve immediately as bark begins to melt 15 minutes after removing from freezer. Nutritional information per serving: 70 calories; 2 g total fat; 3 mg cholesterol; 15 mg sodium; 10 g carbohydrates; 1 g fiber; 9 g total sugars; 4 g protein. Michael Frenchmfrench@ About Family Features Editorial SyndicateA leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at and View original content to download multimedia: SOURCE Family Features Editorial Syndicate
Yahoo
2 hours ago
- Yahoo
Brachytherapy Devices Market is Growing at CAGR of 6.7% During 2025 -2031 to Reach US$534.20 Million
NEW YORK, Aug 4, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the Brachytherapy Devices Market is witnessing significant growth due to the rising incidence of cancer worldwide and technological advancements in brachytherapy devices. The Brachytherapy Devices Market value is expected to reach US$534.20 million by 2031 from US$343.57 million in 2024; the market is anticipated to register a CAGR of 6.7% during 2025–2031. The market growth is attributed to the rising incidence of cancer worldwide, the aging population, and the technological advancements in brachytherapy devices. The Brachytherapy Devices Market analysis focuses on advancements such as MRI-compatible applicators and real-time imaging integration that play a vital role in the market growth. The report runs an in-depth analysis of market trends, key players, and future opportunities. Check valuable insights in the Brachytherapy Devices Market report. You can easily get a sample PDF of the report - Overview of Brachytherapy Devices Market Report Findings Rising Incidence of Cancer Worldwide:As per the GLOBOCAN 2020 report, more than 28.4 million new cancer cases are expected to be reported by 2040. An aging population, lack of physical activity, exposure to pollutants in the environment, and alterations in diet lead to increased rates of an internal radiation treatment, is ideal for the treatment of prostate, cervical, breast, and skin cancers. It allows for the radiation to be targeted directly to the tumor and avoid the surrounding healthy tissues, with reduced side effects and improved recovery times. Thus, brachytherapy is becoming increasingly popular among oncologists and cancer remains among the major causes of mortality globally, demand for effective, low-invasive, and affordable treatment procedures is rising. Brachytherapy is meeting this demand, particularly in facilities where it might not be possible to access highly advanced external radiation facilities. Thus, the increasing burden of cancers worldwide propels the market growth. Technological Advancements in Brachytherapy Devices:Advances in the area are improving the accuracy, safety, and effectiveness of treatments, making brachytherapy a progressively appealing choice for cancer technological advancements include the creation of high-dose rate (HDR) and low-dose rate (LDR) machines, which provide more accurate radiation delivery. HDR machines provide for administering higher doses of radiation in shorter times, making treatment faster and more convenient for patients. MRI-compatible applicators and integration of sophisticated imaging are providing better tumor localization and online monitoring of treatment. These advances allow clinicians to target tumors effectively with less exposure to healthy tissues in the proximity. The robot-assisted platforms provide higher accuracy and precision, particularly in challenging anatomical areas. In addition, miniaturization and mobility of brachytherapy equipment are facilitating treatments, especially in developing advances in technology are making brachytherapy more effective and safer but and increasing its uses in treating a broader spectrum of cancers. Consequently, the greater uptake of these machines is contributing to their adoption and setting the limits of cancer treatment even higher. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on Brachytherapy Devices Market Trends: Brachytherapy Devices Market Segmentation Based on product, the Brachytherapy Devices Market is segmented into seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy. The brachytherapy afterloaders segment held the largest market share in 2024. In terms of type, the Brachytherapy Devices Market is categorized into high-dose rate brachytherapy implant and low-dose rate brachytherapy implant. The low-dose rate brachytherapy implant segment dominated the market in 2024. By application, the Brachytherapy Devices Market is segmented into breast cancer, cervical cancer, prostate cancer, lung cancer, and others. The prostate cancer segment dominated the market in 2024. Per end user, the Brachytherapy Devices Market is divided into hospitals and specialty clinics, ambulatory surgical centers, and others. The hospitals and specialty clinics segment dominated the market in 2024. The Brachytherapy Devices Market is segmented into five major regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Competitive Strategy and Development Key players: Elekta, Varian Medical Systems, Inc., BEBIG Medical, Theragenics Corporation, IsoAid, Siemens Healthineers AG, BXTA, BD, and Eckert and Ziegler are among the major companies operating in the Brachytherapy Devices Market. Trending topics: Advancements in Imaging Technologies, Government Initiatives and Cancer Treatment Programs, Technological Advancements in Brachytherapy Devices, Integration of Artificial Intelligence (AI) and Robotics in brachytherapy, etc. Headlines on Brachytherapy Devices Market Artemis Hospital Announces the Launch of Brachytherapy Services, Expanding Advanced Cancer Care Papua New Guinea Resumes Radiotherapy, Starts Brachytherapy Services with IAEA Support BEBIG Medical Launches SagiNova Brachytherapy System at Father Muller Hospital as a Part of New Healthcare Wing Medanta Patents MAOLO Brachytherapy Device For Advanced Cervical Cancer Treatment Elekta Expands Brachytherapy Portfolio With Acquisition of iCad Inc.'s Xoft Business CivaTech Oncology Receives FDA Approval for CivaSheet Brachytherapy Device Get Premium Copy of Brachytherapy Devices Market Size and Growth Report by 2031 at: Conclusion The growth of the Brachytherapy Devices Market is fueled by the increasing prevalence of cancer, advances in technology, and soaring demand for minimally invasive treatment options. The high-dose rate (HDR) systems, MRI-compatible applicators, and robotic-assisted devices are increasing the accuracy of treatment and speeding up patient recovery. Further, there is a growing demand for affordable and patient-centric therapies, particularly in areas that have poor access to conventional cancer therapy. With increasing uses in prostate, breast, and cervical cancers, the demand for brachytherapy is surging, with better results and accessibility in cancer therapy. The report from The Insight Partners provides several stakeholders—including manufacturers of seeds, brachytherapy afterloaders and applicators, and electronic brachytherapy devices—with valuable insights to navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: Brachytherapy After Loaders Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031 Cancer Therapy Market Scope, Share, and Size by 2031 Pancreatic Cancer Therapy Market SWOT Analysis by 2031 Lung Cancer Therapy Market Research Report by 2030 Cancer Biopsies Market Trends, Share, and Growth – 2031 Cervical Cancer Diagnostics and Therapeutics Market Size 2031 Kidney Cancer Therapeutics And Diagnostics Market Size 2031 Cancer Biopsies Market Trends, Share, and Growth - 2031 Thyroid Cancer Diagnostics Market Growth and Share by 2031 About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us:If you have any queries about this report or if you would like further information, please get in touch with us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Logo: View original content: SOURCE The Insight Partners Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
4 hours ago
- Business Wire
Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference Share Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors throughout the conference. To arrange a meeting, please visit the conference website here or contact your CG representative. A replay of the fireside chat webcast will be available on the Niagen Bioscience Investor Relations website, following the event. For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States † (available at and Niagen Plus ™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).
